All G Secures $6.6M Funding and Partners to Expand Human and Bovine Lactoferrin Production

Key Takeaways

All G partners with Armor Protéines to produce human and bovine lactoferrin through precision fermentation, launching its first product in Q1 2026.
Lactoferrin, an iron-binding protein, offers health benefits but has been difficult to source; All G’s method promises scalable production and quality.
With approvals in the US and ongoing efforts in China, All G plans to tap into infant formula markets, leveraging Armor Protéines’ established distribution network.

Joint Venture Announcement

Australian startup All G has created a joint venture with French dairy specialist Armor Protéines to commercialize human and bovine lactoferrin, harnessing precision fermentation technology. The alliance blends All G’s capabilities in recombinant proteins with Armor Protéines’ expertise in bioactive dairy components. The first product, recombinant bovine lactoferrin, is set to launch in the first quarter of 2026, followed by human lactoferrin later that year.

Funding and Market Potential

All G recently raised A$10 million (around $6.6 million) through a convertible note from prominent investors, including Agronomics and Döhler Ventures, as it prepares for a Series B fundraising round. The startup aims to leverage Armor Protéines’ extensive distribution channels and industry relationships, especially in sectors like infant formula and dietary supplements.

Health Benefits and Production Challenges

Lactoferrin, an antimicrobial protein found in mammalian milk, plays a crucial role in immune function and overall health. Its extraction has traditionally been limited due to the vast amounts of milk required, making it expensive to source. Through precision fermentation, All G aims to overcome these challenges and bring lactoferrin to a broader market in adult nutrition, skincare, and infant products.

Despite these advancements, All G acknowledges technical barriers that have previously hindered production, particularly in replicating glycosylation patterns needed for effectiveness. The company claims to have resolved these issues, resulting in high-quality, pure lactoferrin that is more accessible globally.

Market Strategy and Regulatory Approval

The CEO of All G, Jan Pacas, emphasized that unlike other startups focused on creating entirely new markets, this collaboration with Armor Protéines aims to fulfill existing demand. Armor Protéines is already a significant player in the lactoferrin market, allowing All G to capitalize on established customer relationships.

In terms of compliance, All G has received self-GRAS status in the US and has gained approval to market in various segments within China. This positions the company to scale up effectively, with plans for partnerships with contract manufacturers both in China and elsewhere.

Future Prospects in Infant Formula

While All G currently lacks approval for infant formula sales, it sees significant potential for human lactoferrin in this market, which is valued at $35 billion in China. Working with major players in infant formula, the company is aspiring to navigate the regulatory landscape within the next decade.

In addition to lactoferrin, All G is developing recombinant casein. However, lactoferrin is prioritized due to higher profit margins and immediate market demand. Pacas believes that in the future, human lactoferrin will gain dominance in infant nutrition products.

All G is optimistic about its role in delivering high-quality, bioactive proteins that can significantly benefit consumers, especially babies, when placed against traditional animal-sourced alternatives.

The content above is a summary. For more details, see the source article.